Literature DB >> 30554202

Clinical Outcomes of Patients with Small Rectal Neuroendocrine Tumors Treated Using Endoscopic Submucosal Resection with a Ligation Device.

Maiko Takita1, Eiji Sakai1, Tomomi Nakao1, Yoshiaki Kimoto1, Rindo Ishii1, Takafumi Konishi1, Sakaya Ueno1, Keisuke Kanda1, Ryoju Negishi1, Takashi Muramoto1, Hirotsugu Hashimoto2, Teppei Morikawa2, Nobuyuki Matsuhashi1, Ken Ohata3.   

Abstract

BACKGROUND/AIMS: The therapeutic strategies for small rectal neuroendocrine tumors (NETs) have not been standardized. We examined the efficacy and safety of endoscopic submucosal resection with a ligation device (ESMR-L) and the long-term outcomes after endoscopic treatment.
METHODS: A total of 181 patients with rectal NETs <10 mm who were treated between May 2002 and May 2017 were retrospectively enrolled. All the lesions had been resected using ESMR-L, and the follow-up strategies were determined according to the pathological examinations. The long-term outcomes after a 53-month follow-up period were also evaluated.
RESULTS: R0 resection was achieved in 180 cases (99.4%). Lymphovascular invasion was confirmed in 67 cases (37.0%), while a curative resection was achieved in 114 cases (63.0%). One perforation (0.6%) and 11 cases with delayed bleeding (6.1%) were observed. A multivariate logistic regression analysis revealed that a tumor size > 5 mm (OR 2.06; 95% CI 1.04-4.08, p = 0.04) was a significant independent predictor of the presence of lymphovascular invasion. Of the 67 patients with non-curative resections, 11 patients underwent additional surgery; lymph node metastasis was confirmed in 2 cases (18.2%). No local or distant metastases were observed during the follow-up period in 77 patients with a curative resection, 9 patients who received additional surgery, and 50 patients with non-curative resections.
CONCLUSION: ESMR-L is an easy, safe and effective treatment for rectal NETs <10 mm in diameter, and the prognosis of patients seems to be good, despite a relatively high rate of lymphovascular invasion.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Endoscopic submucosal resection with a ligation device; Endoscopic treatment; Prognosis; Rectal neuroendocrine tumor

Mesh:

Year:  2018        PMID: 30554202     DOI: 10.1159/000494416

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Comparison between endoscopic mucosal resection with a cap and endoscopic submucosal dissection for rectal neuroendocrine tumors.

Authors:  Xiuli Zheng; Mingli Wu; Huihui Shi; Limian Er; Kan Wang; Ying Cao; Shengmian Li
Journal:  BMC Surg       Date:  2022-06-27       Impact factor: 2.030

Review 2.  Management of Gastrointestinal Neuroendocrine Tumors.

Authors:  Rongzhi Wang; Rui Zheng-Pywell; H Alexander Chen; James A Bibb; Herbert Chen; J Bart Rose
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-10-24

3.  A nationwide, multi-institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan.

Authors:  Tatsuro Yamaguchi; Keiichi Takahashi; Kazutaka Yamada; Hiroyuki Bando; Hideo Baba; Masaaki Ito; Kimihiko Funahashi; Hideki Ueno; Shin Fujita; Seiji Hasegawa; Yoshiharu Sakai; Kenichi Sugihara
Journal:  Ann Gastroenterol Surg       Date:  2020-11-17

Review 4.  Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?

Authors:  Jack Cope; Raj Srirajaskanthan
Journal:  Curr Oncol Rep       Date:  2022-01-27       Impact factor: 5.075

Review 5.  Underwater endoscopic mucosal resection for colorectal lesions: Can it be an "Underwater" revolution?

Authors:  Yoji Takeuchi; Satoki Shichijo; Noriya Uedo; Ryu Ishihara
Journal:  DEN open       Date:  2022-01-09

6.  Relevant risk factors and the prognostic impact of positive resection margins after endoscopic resection of gastrointestinal neuroendocrine tumors.

Authors:  Jing Wen; Bin Yan; Jing Yang; Zhongsheng Lu; Xuqiang Bian; Jin Huang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-11-04       Impact factor: 1.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.